Prostate Cancer (MSK, Cell Metab 2020)

Summary

Prostate Cancer (MSK, Cell Metab 2020) is a study catalogued by cBioPortal DataHub under the cancer-type code prostate. EvidenceHelix groups it with prostate studies.

Study description

MSK-IMPACT Sequencing of 18 prostate cancer tumor/normal pairs.

Text as published in the source's study metadata.

Citation & PubMed

Granlund et al. Cell Metab 2020

Linked PubMed records: PMID 31564440

Source & licence

Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.

Source metadata

Study identifier

prad_msk_2019

Short name

PROSTATE (MSK 2019)

Source cancer-type code

prostate

Reference genome

not given

Source access groups

PUBLIC

Original study

View on cBioPortal

Metadata file

meta_study.txt at e1b75cd25b

Database licence

ODC Open Database License (ODbL) 1.0

Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data.

Citations

Granlund et al. Cell Metab 2020

• PubMed record 31564440 ↗

Citation counts are not part of the source metadata and are not shown.

Related studies

• Prostate Cancer (MSK, Clin Cancer Res 2024)

  Targeted sequencing of 2,257 prostate cancer patient samples and their matched normals via MSK-IMPACT platform. This data is available under the Creative Commons BY-NC-ND 4.0 license (https://creativecommons.org/licen…

  ProstateMSK studiesSource code prostatePubMed 1

• Prostate Cancer (DKFZ, Cancer Cell 2018)

  Whole genome and transcriptome sequencing of tumor/normal pairs from 292 prostate cancer patients.

  ProstateOther published and consortium studiesSource code prostatePubMed 1

• Prostate Cancer Brain Metastases (Bern, Nat Commun. 2022)

  Prostate Cancer Brain Metastases, Switzerland. Dataset was generated in 2019 by Antonio Rodriguez, John Gallon, Salvatore Piscuoglio and Mark Rubin.

  ProstateOther published and consortium studiesSource code prostatePubMed 1

• Prostate Cancer MDA PCa PDX (MD Anderson, Clin Cancer Res 2024)

  Targeted sequencing and whole-genome sequencing of 88 MD Anderson Prostate Cancer PDX models derived from 38 patients with tumor.

  ProstateOther published and consortium studiesSource code prostatePubMed 1

• The Metastatic Prostate Cancer Project (Provisional, June 2021)

  The Metastatic Prostate Cancer Project is a patient-driven initiative. This study includes genomic data, cfDNA tumor fractions, patient-reported data (pre-pended as PRD), medical record data (MedR), and pathology repo…

  ProstateOther published and consortium studiesSource code prostate

• Metastatic castration-sensitive prostate cancer (MSK, Clin Cancer Res 2020)

  MSK-IMPACT sequencing of 424 matched tumor-normal samples from patients with metastatic castration-sensitive prostate cancer. Germline alterations are not shown here.

  ProstateMSK studiesSource code pradPubMed 1

• Prostate Adenocarcinoma (MSK, Cancer Cell 2010)

  Comprehensive profiling of 218 prostate tumors (181 primaries, 37 metastases) and 14 prostate cancer cell lines and xenografts. MSKCC Prostate Oncogenome Project. Normalized flat data files (http://cbio.mskcc.org/canc…

  ProstateMSK studiesSource code pradPubMed 1

• Prostate Adenocarcinoma (MSK, Clin Cancer Res. 2022)

  Targeted sequencing of 1417 Prostate Adenocarcinoma tumor/normal sample pairs via MSK-IMPACT to analyze the significance of PIK3R1 alterations.

  ProstateMSK studiesSource code pradPubMed 1

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.